[go: up one dir, main page]

ECSP10010446A - Uso de ranolazina para el tratamiento del dolor - Google Patents

Uso de ranolazina para el tratamiento del dolor

Info

Publication number
ECSP10010446A
ECSP10010446A EC2010010446A ECSP10010446A ECSP10010446A EC SP10010446 A ECSP10010446 A EC SP10010446A EC 2010010446 A EC2010010446 A EC 2010010446A EC SP10010446 A ECSP10010446 A EC SP10010446A EC SP10010446 A ECSP10010446 A EC SP10010446A
Authority
EC
Ecuador
Prior art keywords
ranolazine
pain
treatment
patient
visceral
Prior art date
Application number
EC2010010446A
Other languages
English (en)
Inventor
Ivan Diamond
Luiz Belardinelli
John Shryock
Sridharan Rajamani
Original Assignee
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc
Publication of ECSP10010446A publication Critical patent/ECSP10010446A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se relaciona con métodos para tratar un paciente que sufre de dolor neuropático o nociceptivo que puede ser de naturaleza mecánica, visceral y/o inflamatoria, que comprende administrar una cantidad terapéuticamente efectiva de Ranolazina a un paciente necesitado de la misma.
EC2010010446A 2008-02-06 2010-09-03 Uso de ranolazina para el tratamiento del dolor ECSP10010446A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2669908P 2008-02-06 2008-02-06
US5743708P 2008-05-30 2008-05-30

Publications (1)

Publication Number Publication Date
ECSP10010446A true ECSP10010446A (es) 2010-10-30

Family

ID=40548472

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010446A ECSP10010446A (es) 2008-02-06 2010-09-03 Uso de ranolazina para el tratamiento del dolor

Country Status (13)

Country Link
US (1) US20090203707A1 (es)
EP (1) EP2252294A1 (es)
KR (1) KR20110013348A (es)
CN (1) CN101977605A (es)
AU (1) AU2009212254A1 (es)
BR (1) BRPI0908428A2 (es)
CA (1) CA2713521A1 (es)
CO (1) CO6290663A2 (es)
EA (1) EA201070914A1 (es)
EC (1) ECSP10010446A (es)
IL (1) IL207292A0 (es)
MA (1) MA32132B1 (es)
WO (1) WO2009100380A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099281A2 (en) 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
CA2761771A1 (en) * 2009-05-14 2010-11-18 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
LT2464645T (lt) 2009-07-27 2017-10-25 Gilead Sciences, Inc. Kondensuoti heterocikliniai junginiai, kaip jonų kanalų moduliatoriai
US8703759B2 (en) 2010-07-02 2014-04-22 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (es) 2011-07-01 2018-04-28
SG11201604457XA (en) 2013-12-19 2016-07-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
EP3548033B1 (en) 2016-11-28 2024-04-10 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
AU2019278814B2 (en) 2018-05-30 2025-12-18 Praxis Precision Medicines, Inc. Ion channel modulators
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
KR20220119624A (ko) 2019-11-26 2022-08-30 프락시스 프리시젼 메디신즈, 인크. 이온 채널 조절제
EP4065114B1 (en) 2019-11-27 2025-11-05 Praxis Precision Medicines, Inc. Method for making relutrigine/prax-562
WO2021119157A1 (en) 2019-12-11 2021-06-17 Duke University Small molecule inhibitors of voltage-gated sodium channel 1.7 and methods of using same
WO2025252860A1 (en) * 2024-06-04 2025-12-11 Celex Oncology Innovations Limited Ranolazine enantiomer for use in cancer treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657264A (en) * 1985-11-01 1987-04-14 Ingersoll-Rand Company Fluid seal assembly with segmented sub-assembly
ES2091211T3 (es) * 1989-06-23 1996-11-01 Syntex Inc Ranolazina y piperazinas relacionadas utilizadas en el tratamiento de tejidos que sufren una lesion fisica o quimica.
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
HK1048250A1 (zh) * 2000-02-18 2003-03-28 Cv Therapeutics, Inc. 在治疗充血性心力衰竭中使用的部分脂肪酸氧化抑制剂
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2003099281A2 (en) * 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
GEP20094784B (en) * 2005-01-06 2009-09-25 Cv Therapeutics Inc Sustained release pharmaceutical formulations
US20070203079A1 (en) * 2005-11-21 2007-08-30 Caldwell Guy A Methods of using small molecule compounds for neuroprotection
CA2653056A1 (en) * 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
JP2010518169A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
US7951813B2 (en) * 2007-04-05 2011-05-31 Gilead Sciences, Inc. Quinazolinone derivatives as ALDH-2 inhibitors
US20080255031A1 (en) * 2007-04-12 2008-10-16 Arvinder Dhalla Method for enhancing insulin secretion
BRPI0820440A2 (pt) * 2007-11-06 2015-05-26 Cv Therapeutics Inc Inibidores aldh-2 no tratamento de desordens psiquiátricas

Also Published As

Publication number Publication date
US20090203707A1 (en) 2009-08-13
KR20110013348A (ko) 2011-02-09
WO2009100380A1 (en) 2009-08-13
IL207292A0 (en) 2010-12-30
CN101977605A (zh) 2011-02-16
MA32132B1 (fr) 2011-03-01
CO6290663A2 (es) 2011-06-20
BRPI0908428A2 (pt) 2015-12-08
AU2009212254A1 (en) 2009-08-13
CA2713521A1 (en) 2009-08-13
EA201070914A1 (ru) 2011-04-29
EP2252294A1 (en) 2010-11-24

Similar Documents

Publication Publication Date Title
ECSP10010446A (es) Uso de ranolazina para el tratamiento del dolor
CY1124103T1 (el) Δοσολογικο σχημα που σχετιζεται με ενεσιμους εστερες παλιπεριδονης μακρας δρασης
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
HN2012000297A (es) Composicion para tratar la fibrosis quistica
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
CR20110560A (es) Métodos de tratamiento para tumores sólidos
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PH12012500916B1 (en) Treatments for gastrointestinal disorders
EA201001865A1 (ru) Противовоспалительные агенты
CL2008000896A1 (es) Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal.
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
CY1117184T1 (el) ΤΕΛΕΣΤΕΣ β-ΑΡΡΕΣΤΙΝΗΣ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΚΑΙ ΜΕΘΟΔΟΙΧΡΗΣΗΣ ΑΥΤΩΝ
EA201200428A1 (ru) Композиция и способ для лечения ожирения
CY1117251T1 (el) Μεθοδοι θεραπευτικης αντιμετωπισης της σκληροδερμιας
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.